CRSP

CRISPR Therapeutics AG

Halal Rating :
Comfortable
Last Price $40.71 Last updated:
Market Cap $4.06b
7D Change -7.01%
1 Year Change -32.82%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 4, 2024

CRISPR Therapeutics AG is a gene editing company focused on developing transformative gene-based medicines for serious diseases. The company's core technology is based on CRISPR/Cas9, a revolutionary gene editing tool that allows for precise, directed changes to genomic DNA. The company is developing treatments for various genetic diseases, blood disorders, cancer, and other conditions.

The company's lead product candidate, CASGEVY™ (exagamglogene autotemcel), developed in collaboration with Vertex Pharmaceuticals, recently received FDA approval for the treatment of sickle cell disease and transfusion-dependent beta thalassemia.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $602000.0 $110.73m - - 0.00% 0.00%
June 30, 2024 $517000.0 $151.78m - - 0.00% 0.00%
March 31, 2024 $504000.0 $141.09m - - 0.00% 0.00%

Company Impact

Help us evaluate CRISPR Therapeutics AG's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates